Total number of included studies | Hong [29] | Kaneda [33] | Kernan (IRIS) [2] | Lee [30] | Nishio [34] | Nissen (PERISCOPE) [9] | Suryadevara [31] | Takagi (POPPS) [32] | Tanaka (J-SPIRIT) [8] | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Population | |||||||||||
Type 2 diabetes + CVD | 7 | X | X | X | X | X | X | X | |||
Type 2 diabetes + no diabetes + CVD | 1 | X | |||||||||
Abnormal glucose metabolism without diabetes + CVD | 2 | X | X | ||||||||
Patients undergoing PCI | 5 | X | X | X | X | X | |||||
Type of pioglitazone treatment | |||||||||||
Pioglitazone 15 mg/d | 2 | X | X | ||||||||
Pioglitazone 30 mg/d | 3 | X | X | X | |||||||
Pioglitazone 45 mg/d | 1 | X | |||||||||
Pioglitazone 15–30 mg/d | 2 | X | X | ||||||||
Pioglitazone 15–45 mg/d | 2 | X | X | ||||||||
Treatment in control group | |||||||||||
None | 4 | X | X | X | X | ||||||
Placebo | 5 | X | X | X | X | X | |||||
Glimepiride | 1 | X | |||||||||
Extracted outcome of interest | |||||||||||
Major adverse c cardiac/Cardiovascular disease | 8 | X | X | X | X | X | X | X | X | ||
Myocardial infarction | 8 | X | X | X | X | X | X | X | X | ||
Stroke | 4 | X | X | X | X | ||||||
All-cause mortality | 8 | X | X | X | X | X | X | X | X | ||
Heart failure | 6 | X | X | X | X | X | X | X |